Shock in myocardial infarction--medical treatment.
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D003331:Coronary Vessels / Q000187:drug effects; D004071:Digitalis Glycosides / Q000627:therapeutic use; D004285:Dogs; D004298:Dopamine / Q000627:therapeutic use; D005934:Glucagon / Q000627:therapeutic use; D005947:Glucose / Q000008:administration & dosage; D006321:Heart / Q000503:physiopathology; D006439:Hemodynamics; D006801:Humans; D006931:Hyperbaric Oxygenation; D007263:Infusions, Parenteral; D007545:Isoproterenol / Q000494:pharmacology / Q000627:therapeutic use; D007773:Lactates / Q000097:blood; D009203:Myocardial Infarction / Q000097:blood / Q000150:complications* / Q000503:physiopathology; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption / Q000187:drug effects; D010952:Plasma Substitutes / Q000627:therapeutic use; D011773:Pyruvates / Q000097:blood; D012039:Regional Blood Flow / Q000187:drug effects; D012770:Shock, Cardiogenic / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D014655:Vascular Resistance / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use
D004071:Digitalis Glycosides; D007773:Lactates; D010952:Plasma Substitutes; D011773:Pyruvates; D014662:Vasoconstrictor Agents; D005934:Glucagon; D005947:Glucose; D007545:Isoproterenol; D010100:Oxygen; D004298:Dopamine